Imbruvica is the leading systemic therapy for relapsed/refractory CLL
While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica. Datamonitor Healthcare surveyed 218 hematologists and hematologist-oncologists across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK) to gain an understanding of current and future prescribing patterns for CLL. While the survey results clearly demonstrated that Rituxan-based regimens are still the foundation for the pharmacological treatment of CLL, Imbruvica is gaining increasing uptake among patients whose disease has recurred. Historically, outcomes and response rates for patients with relapsed/refractory CLL have been poor and this treatment setting has been a major area of unmet need. However, Imbruvica has gained significant uptake following its accelerated US FDA approval in February 2014 due to the drug’s superior efficacy and tolerability in patients with relapsed/refractory CLL when compared with other chemoimmunotherapy agents such as Genmab and Novartis’s Arzerra. These positive data from Imbruvica’s RESONATE trial (ClinicalTrials.gov identifier: NCT01578707) also led to its approval in the EU and Japan. As shown in the table below, Datamonitor Healthcare’s survey highlighted that physicians currently prescribe Imbruvica heavily in the relapsed/refractory CLL setting.
Percentage of patients receiving Imbruvica across all surveyed markets (US, Japan, and five major EU markets), by stage and line of therapy (%)
|Stage||Line of Therapy||Imbruvica|
Source: Datamonitor Healthcare’s proprietary chronic lymphocytic leukemia survey, August 2016
Datamonitor Healthcare’s Chronic Lymphocytic Leukemia: Treatment reveals how CLL patients are currently managed, and outlines the disease’s greatest unmet needs.